HKSE - Delayed Quote HKD
Beijing Biostar Pharms Co Ltd (2563.HK)
4.410
-0.930
(-17.42%)
At close: March 31 at 4:08:28 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
Total Revenue
68,152
66,635
32,820
Cost of Revenue
15,367
19,810
8,940
Gross Profit
52,785
46,825
23,880
Operating Expense
239,717
264,804
224,018
Operating Income
-186,932
-217,979
-200,138
Net Non Operating Interest Income Expense
14,618
13,081
3,270
Pretax Income
-163,668
-189,644
-160,511
Tax Provision
0
0
0
Net Income Common Stockholders
-163,668
-189,644
-160,511
Diluted NI Available to Com Stockholders
-163,668
-189,644
-160,511
Total Operating Income as Reported
-163,615
-189,587
-160,440
Total Expenses
255,084
284,614
232,958
Net Income from Continuing & Discontinued Operation
-163,668
-189,644
-160,511
Normalized Income
-167,883
-200,025
-170,148
Interest Income
14,671
13,138
3,341
Interest Expense
53
57
71
Net Interest Income
14,618
13,081
3,270
EBIT
-163,615
-189,587
-160,440
EBITDA
-153,059
-178,965
-149,938
Reconciled Cost of Revenue
15,367
19,810
8,940
Reconciled Depreciation
10,556
10,622
10,502
Net Income from Continuing Operation Net Minority Interest
-163,668
-189,644
-160,511
Total Unusual Items Excluding Goodwill
4,215
10,381
9,637
Total Unusual Items
4,215
10,381
9,637
Normalized EBITDA
-157,274
-189,346
-159,575
Tax Rate for Calcs
0
0
0
Tax Effect of Unusual Items
0
0
0
12/31/2022 - 10/31/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade